The Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2021 report provides a detailed understanding and analysis of how and why companies enter in vitro diagnostics partnering deals.
These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest In Vitro Diagnostics agreements announced in the life sciences since 2014.
The report takes the reader through a comprehensive review In Vitro Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering In Vitro Diagnostics partnering deals.
The report presents financial deal term values for In Vitro Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the In Vitro Diagnostics partnering field; both the leading deal values and most active In Vitro Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 600 online deal records of actual In Vitro Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of In Vitro Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in In Vitro Diagnostics dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading In Vitro Diagnostics deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in In Vitro Diagnostics dealmaking with a brief summary followed by a comprehensive listing of In Vitro Diagnostics deals announded by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of In Vitro Diagnostics partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of In Vitro Diagnostics partnering deals signed and announced since Jan 2014. The chapter is organized by specific In Vitro Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by In Vitro Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in In Vitro Diagnostics partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of In Vitro Diagnostics technologies and products.
Key benefits Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2021 provides the reader with the following key benefits: In-depth understanding of In Vitro Diagnostics deal trends since 2014 Access to headline, upfront, milestone and royalty data Detailed access to actual In Vitro Diagnostics contracts entered into by leading biopharma companies Identify most active In Vitro Diagnostics dealmakers since 2014 Insight into terms included in a In Vitro Diagnostics partnering agreement, with real world examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2021 is intended to provide the reader with an in-depth understanding and access to In Vitro Diagnostics trends and structure of deals entered into by leading companies worldwide.
In Vitro Diagnostics Partnering Terms and Agreements includes: Trends in In Vitro Diagnostics dealmaking in the biopharma industry since 2014 Analysis of In Vitro Diagnostics deal structure Access to headline, upfront, milestone and royalty data Access to In Vitro Diagnostics contract documents Leading In Vitro Diagnostics deals by value since 2014 Most active In Vitro Diagnostics dealmakers since 2014
In Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2021, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2021 report provides comprehensive access to available deals and contract documents for over 600 In Vitro Diagnostics deals.
Analyzing actual contract agreements allows assessment of the following: • What are the precise rights granted or optioned? • What is actually granted by the agreement to the partner company? • What exclusivity is granted? • What is the payment structure for the deal? • How are sales and payments audited? • What is the deal term? • How are the key terms of the agreement defined? • How are IPRs handled and owned? • Who is responsible for commercialization? • Who is responsible for development, supply, and manufacture? • How is confidentiality and publication managed? • How are disputes to be resolved? • Under what conditions can the deal be terminated? • What happens when there is a change of ownership? • What sublicensing and subcontracting provisions have been agreed? • Which boilerplate clauses does the company insist upon? • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? • Which jurisdiction does the company insist upon for agreement law?
Our reports have been used by over 10K customers, including:
The in-vitro diagnostics market in South and Central America is expected to grow from US$ 4,387.7 million in 2019 to US$ 5,820.0 million by 2027; it is estimated to grow at a CAGR of 3.6% from 2020 to 2027. Automation deals with the utilization of various intelligent systems with an aim to perform any operation with minimal human intervention....
400 pages •
By The Business Research Company
• Feb 2021
Major companies in the in-vitro diagnostics market include Siemens Healthineers; F. Hoffmann-La Roche Ltd; Danaher (Beckman Coulter Inc); Abbott Laboratories Inc and Thermo Fisher Scientific Inc. The global in-vitro diagnostics market is expected to grow from $71.71 billion in 2020 to $80.12 billion in 2021 at a compound annual growth...
Report Scope Traditional medical devices include devices (e.g., metallic stents, heart valves, open procedures, general instruments, non-drug coated implantables, large endoscopes, needle-based drug delivery, lab-based diagnostics, etc.) that have been in use over the last 30 years for the treatment and management of various...
Global Cell Isolation Market By Product (Consumables and Instruments), By Cell Type (Human Cells and Animal Cells), By Source (Bone Marrow, Cord Blood/Embryonic Stem Cells, Adipose Tissue), By Technique (Centrifugation-Based Cell Isolation, Surface Marker-Based Cell Isolation, Filtration-Based Cell Isolation), By Application (Biomolecule...
The GCC in-vitro diagnostic devices market reached a value of US$ 1,233 Million in 2020. In-vitro diagnostics (IVD) refer to the clinical tests conducted on different bodily samples, such as urine, tissue and blood, to detect diseases and infections. These tests are also employed to monitor the health conditions of...
China In-Vitro Diagnostics (IVD) market is predicted to exceed US$ 21 Billion by 2027. China is a large and fast-growing in vitro diagnostics (IVD) market - in fact, only second to the United States in terms of value. Historically, large multinational companies have dominated IVD market in China; today, domestic companies such as Shanghai...
Japan In Vitro Diagnostics (IVD) market is predicted to exceed US$ 4.7 Billion mark by 2027. Japan represents one of the largest clinical laboratory markets in the Asia–Pacific region, and the fastest growing among the top ten IVD country markets. With an aging population, technological advances and advent of point of care diagnostics, Japanese...
The in-vitro diagnostics market in Asia Pacific is expected to grow from US$ 13,729.8 million in 2019 to US$ 20,401.5 million by 2027; it is estimated to grow at a CAGR of 5.1% from 2020 to 2027. Incidence of chronic diseases such as cancers, chronic respiratory diseases, diabetes, and heart disease is growing due to biological risk factors,...
The in-vitro diagnostics market in Europe is expected to grow from US$ 15,973.0 million in 2019 to US$ 22,221.8 million by 2027; it is estimated to grow at a CAGR of 4.2% from 2020 to 2027. The in-vitro diagnostics market has accounted for a significant market share in the healthcare industry during the COVID-19 pandemic. The market growth...
In Vitro Diagnostics
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.